Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 837

1.

Development and validation of the caregiver roles and responsibilities scale in cancer caregivers.

Shilling V, Starkings R, Jenkins V, Cella D, Fallowfield L.

Qual Life Res. 2019 Mar 18. doi: 10.1007/s11136-019-02154-4. [Epub ahead of print]

PMID:
30887387
2.

Bifactor analysis confirmation of the factorial structure of the Functional Assessment of Cancer Therapy - General (FACT-G).

Peipert JD, Cella D.

Psychooncology. 2019 Mar 18. doi: 10.1002/pon.5062. [Epub ahead of print] No abstract available.

PMID:
30883962
3.

Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients.

Degboe A, Ivanescu C, Rohay JM, Turner RR, Cella D.

Support Care Cancer. 2019 Mar 1. doi: 10.1007/s00520-019-04709-0. [Epub ahead of print]

PMID:
30825026
4.

Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System.

Ezeife DA, Morganstein BJ, Lau S, Law JH, Le LW, Bredle J, Cella D, Doherty MK, Bradbury P, Liu G, Sacher A, Shepherd FA, Leighl NB.

Clin Lung Cancer. 2018 Dec 22. pii: S1525-7304(18)30334-6. doi: 10.1016/j.cllc.2018.12.010. [Epub ahead of print]

PMID:
30797721
5.

Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss.

Gelhorn HL, Gries KS, Speck RM, Duus EM, Bourne RK, Aggarwal D, Cella D.

Qual Life Res. 2019 Feb 22. doi: 10.1007/s11136-019-02135-7. [Epub ahead of print]

PMID:
30796591
6.

Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings.

Galipeau N, Klooster B, Krohe M, Tang DH, Revicki DA, Cella D.

J Patient Rep Outcomes. 2019 Feb 7;3(1):10. doi: 10.1186/s41687-019-0098-1.

7.

The Comprehensive Assessment of Self-Reported Urinary Symptoms: A New Tool for Research on Subtypes of Patients with Lower Urinary Tract Symptoms.

Weinfurt KP, Griffith JW, Flynn KE, Cella D, Bavendam T, Wiseman JB, Andreev VP, Lai HH, Liu AB, Kirkali Z, Cameron AP, Bradley CS; LURN Study Group.

J Urol. 2019 Feb 5:101097JU0000000000000140. doi: 10.1097/JU.0000000000000140. [Epub ahead of print]

PMID:
30730410
8.

Patient-Reported Outcomes are Important Elements of Psoriasis Treatment Decision Making: A Discrete Choice Experiment Survey of Dermatologists in the United States.

Feldman SR, Regnier SA, Chirilov A, Hey F, Gilloteau I, Cella D.

J Am Acad Dermatol. 2019 Jan 28. pii: S0190-9622(19)30146-X. doi: 10.1016/j.jaad.2019.01.039. [Epub ahead of print]

9.

Meaningful differences and validity for the NCCN/FACT-P symptom index: An analysis of the ALSYMPCA data.

Beaumont JL, Butt Z, Li R, Cella D.

Cancer. 2019 Jan 28. doi: 10.1002/cncr.31973. [Epub ahead of print]

PMID:
30690719
10.

Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial.

Delaloge S, Cella D, Ye Y, Buyse M, Chan A, Barrios CH, Holmes FA, Mansi J, Iwata H, Ejlertsen B, Moy B, Chia SKL, Gnant M, Smichkoska S, Ciceniene A, Martinez N, Filipovic S, Ben-Baruch NE, Joy AA, Langkjer ST, Senecal F, de Boer RH, Moran S, Yao B, Bryce R, Auerbach A, Fallowfield L, Martin M.

Ann Oncol. 2019 Jan 23. doi: 10.1093/annonc/mdz016. [Epub ahead of print]

PMID:
30689703
11.

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.

Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA.

J Patient Rep Outcomes. 2019 Jan 24;3(1):5. doi: 10.1186/s41687-019-0094-5.

12.

Modeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncology.

Cottone F, Deliu N, Collins GS, Anota A, Bonnetain F, Van Steen K, Cella D, Efficace F.

Qual Life Res. 2019 Jan 18. doi: 10.1007/s11136-018-02097-2. [Epub ahead of print]

PMID:
30659449
13.

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.

Cella D, Grünwald V, Escudier B, Hammers HJ, George S, Nathan P, Grimm MO, Rini BI, Doan J, Ivanescu C, Paty J, Mekan S, Motzer RJ.

Lancet Oncol. 2019 Feb;20(2):297-310. doi: 10.1016/S1470-2045(18)30778-2. Epub 2019 Jan 15.

PMID:
30658932
14.

Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03).

Atkinson TM, Palefsky J, Li Y, Webb A, Berry JM, Goldstone S, Levine R, Wilkin TJ, Bucher G, Cella D, Burkhalter JE; ANCHOR HRQoL Implementation Group.

Qual Life Res. 2019 Jan 7. doi: 10.1007/s11136-018-2089-8. [Epub ahead of print]

PMID:
30617704
15.

Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.

Cella D, Motzer RJ, Rini BI, Cappelleri JC, Ramaswamy K, Hariharan S, Arondekar B, Bushmakin AG.

Value Health. 2018 Dec;21(12):1413-1418. doi: 10.1016/j.jval.2018.04.1371. Epub 2018 May 11.

PMID:
30502785
16.

Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR.

Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, Ramage J, Pavel M, Hörsch D, Kulke MH.

Clin Ther. 2018 Dec;40(12):2006-2020.e2. doi: 10.1016/j.clinthera.2018.10.008. Epub 2018 Nov 24.

17.

Inpatient Rehabilitation Quality of Care From the Patient's Perspective: Effect of Data Collection Timing and Patient Characteristics.

Deutsch A, Heinemann AW, Cook KF, Foster L, Miskovic A, Goldsmith A, Cella D.

Arch Phys Med Rehabil. 2018 Nov 23. pii: S0003-9993(18)31473-4. doi: 10.1016/j.apmr.2018.10.019. [Epub ahead of print]

PMID:
30476488
18.

Depressive symptom prevalence after intracerebral hemorrhage: a multi-center study.

Francis BA, Beaumont J, Maas MB, Liotta EM, Cella D, Prabhakaran S, Holl J, Kho A, Naidech AM.

J Patient Rep Outcomes. 2018 Nov 23;2(1):55. doi: 10.1186/s41687-018-0083-0.

19.

Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 and -29 item short forms among kidney transplant recipients.

Tang E, Ekundayo O, Peipert JD, Edwards N, Bansal A, Richardson C, Bartlett SJ, Howell D, Li M, Cella D, Novak M, Mucsi I.

Qual Life Res. 2019 Mar;28(3):815-827. doi: 10.1007/s11136-018-2058-2. Epub 2018 Nov 22.

PMID:
30467780
20.

Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study.

Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D.

Medicine (Baltimore). 2018 Nov;97(47):e13390. doi: 10.1097/MD.0000000000013390.

Supplemental Content

Support Center